Trial Profile
A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs GW 468816 (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- 28 May 2014 New trial record